Journal of South Asian Federation of Obstetrics and Gynaecology

Register      Login

VOLUME 12 , ISSUE 3 ( May-June, 2020 ) > List of Articles


Postmenopausal Alopecia due to Ovarian Hyperandrogenemia Treated with Bilateral Salpingo-oophorectomy

Santanu Acharya, Srirupa Chakravorty, David Rae

Keywords : Bilateral salpingo-oophorectomy, Gonadotropin analogs, Male-pattern baldness, Ovarian hyperandrogenemia, Postmenopausal alopecia

Citation Information : Acharya S, Chakravorty S, Rae D. Postmenopausal Alopecia due to Ovarian Hyperandrogenemia Treated with Bilateral Salpingo-oophorectomy. J South Asian Feder Obs Gynae 2020; 12 (3):182-183.

DOI: 10.5005/jp-journals-10006-1771

License: CC BY-NC 4.0

Published Online: 22-11-2020

Copyright Statement:  Copyright © 2020; Jaypee Brothers Medical Publishers (P) Ltd.


Introduction: Increased ovarian production of androgens due to the stimulation of luteinizing hormone (LH) on theca cells can cause hyperandrogenism that may present with signs of alopecia in postmenopausal women. Case description: A 65-year-old postmenopausal woman presented to the gynecology clinic with male-pattern baldness. Serum testosterone was high that was suppressed with gonadotropin-releasing hormone analog (GnRH agonist). This confirmed ovarian source of androgens. Laparoscopic salpingo-oophorectomy helped reduce androgen levels over a period of an year therefore reversing at least partially the hair loss. Conclusion: Gonadotropin-releasing hormone analogs can be useful to diagnose the source of increased androgen levels to be of ovarian origin. Once confirmed, laparoscopic bilateral salpingo-oophorectomy can reverse hair loss in these cases.

PDF Share
  1. Ovarian androgen production in postmenopausal women. J Clin Endocrinol Metab 2007;92(8):3040–3043. DOI: 10.1210/jc.2007-0581.
  2. Endocrine activity of the postmenopausal ovary: the effects of pituitary down-regulation and oophorectomy. J Clin Endocrinol Metab 1995;80(7):2163–2167. DOI: 10.1210/jc.80.7.2163.
  3. The climacteric ovary as a functional gonadotropin driven androgen-producing gland. Fertil Steril 1994;62(1):20–27. DOI: 10.1016/s0015-0282(16)56810-1.
  4. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metabol 2010;95(5):2038–2049. DOI: 10.1210/jc.2009-2724.
  5. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the national institutes of health – national heart, lung, and blood institute sponsored women's ischemia syndrome svaluation. J Clin Endocrinol Metabol 2008;93(4):1276–1284. DOI: 10.1210/jc.2007-0425.
  6. Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society. Hum Reprod Update 2012;18(2):146–170. DOI: 10.1093/humupd/dmr042.
  7. How should postmenopausal androgen excess be evaluated? Clin Endocrinol (Oxf) 2011;75(2):160–164. DOI: 10.1111/j.1365-2265.2011.04040.x.
  8. Pathogenesis and causes of hirsutism Snyder PJ, Crowley WF Jr, ed. UpToDate in endocrinology and metabolism. Philadelphia: Wolters Kluwer Health; 2012.
  9. Approach to the patient with an adrenal incidentaloma. J Clin Endocrinol Metabol 2010;95(9):4106–4113. DOI: 10.1210/jc.2010-0457.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.